Fifty 1 Labs and UAV Corp Complete Historic REVIVE Trial, Pioneering Long COVID Treatment
Fifty 1 Labs, Inc. and UAV Corp have successfully completed the REVIVE Adaptive Platform Trial, marking a significant advancement in the treatment of Long COVID and positioning the companies for growth in the functional medicine market.
Fifty 1 Labs, Inc. (OTC: FITY) and UAV Corp (OTC: UMAV) have announced the completion of the REVIVE Adaptive Platform Trial (NCT06128967), a landmark Phase III study that stands as the largest Long COVID trial conducted to date. This randomized, double-blind trial, which involved over 600 participants and was conducted in collaboration with global partners and prestigious institutions such as Stanford and Duke, has demonstrated a clear treatment benefit using repurposed medicines. The trial, powered by FITY's proprietary AI platform, not only sets a new benchmark in drug repurposing and personalized medicine but also aligns with the company's strategic goals to dominate the $320.6 billion functional medicine market, explore strategic acquisitions, and progress towards uplisting to OTCQB and Nasdaq.
The success of the REVIVE trial underscores the potential of repurposed medicines in addressing Long COVID, a condition that has affected millions worldwide and for which treatment options have been limited. By leveraging its AI platform, Fifty 1 Labs has showcased the efficacy of a personalized medicine approach, offering hope to patients and signaling a significant step forward in the battle against Long COVID. This achievement not only highlights the company's innovative capabilities but also its commitment to leading the charge in the functional medicine sector. For more details on the trial and its implications, visit https://ibn.fm/Vq9L8.